Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU • Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction ...
Ticker |
Sentiment |
Impact |
REGN
|
Neutral
|
4 %
|
META
|
Neutral
|
1 %
|
SNY
|
Neutral
|
14 %
|